Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - dermatophagoides farinae allergen extract 150 ir ((american house dust mite)); dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) - sublingual tablet - 300 ir - active: dermatophagoides farinae allergen extract 150 ir ((american house dust mite)) dermatophagoides pteronyssinus allergen extract 150 ir ((european house dust mite)) excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - actair is indicated for the treatment of house dust mite allergic rhinitis with or without conjunctivitis in adults, adolescents and children 5 years and over diagnosed with house dust mite allergy.

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

austell pharmaceuticals (pty) ltd - capsules - 20,0 mg - each capsule contains omeprazole 20,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

dezzo trading 392 (pty) ltd - capsules - 20,0 mg - each capsule contains omeprazole 20,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

dezzo trading 392 (pty) ltd - capsules - 20,0 mg - each capsule contains ameprazole 20,0 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

dezzo trading 392 (pty) ltd - capsules - not indicated - none

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - darolutamide, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; calcium hydrogen phosphate; macrogol 3350; titanium dioxide; povidone - nubeqa is indicated for the treatment of patients with: ? non-metastatic castration resistant prostate cancer (nmcrpc) ? metastatic hormone-sensitive prostate cancer (mhspc) in combination with docetaxel

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - darolutamide, quantity: 300 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; calcium hydrogen phosphate; macrogol 3350; titanium dioxide; povidone - nubeqa is indicated for the treatment of patients with: ? non-metastatic castration resistant prostate cancer (nmcrpc) ? metastatic hormone-sensitive prostate cancer (mhspc) in combination with docetaxel

Australia - englanti - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - amlodipine besilate -

Filippiinit - englanti - FDA (Food And Drug Administration)

zuellig pharma corporation - dengue tetravalent vaccine (live, attenuated) (see formulation on reverse side) - powder for suspension for injection sc

Australia - englanti - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 0.5 ml - injection, solution - excipient ingredients: - revestive is indicated for the treatment of adult and paediatric patients 2 years of age and above with short bowel syndrome (sbs) who are dependent on parenteral support.,patients should be stable for at least 4 weeks on their parenteral support regimen before initiating teduglutide therapy